Quantcast
Home > Quotes > CFRX
CFRX

ContraFect Corporation Common Stock (CFRX) Quote & Summary Data

$0.44
*  
0.01
2.33%
Get CFRX Alerts
*Delayed - data as of Feb. 15, 2019  -  Find a broker to begin trading CFRX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
3.15
Today's High / Low
$ 0.45 / $ 0.42
Share Volume
707,309
50 Day Avg. Daily Volume
972,093
Previous Close
$ 0.43
52 Week High / Low
$ 2.9266 / $ 0.355
Market Cap
34,940,205
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.88

Intraday Chart

Shares Traded

Share Volume:
707,309
50 Day Avg. Daily Volume:
972,093

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.65

Trading Range

The current last sale of $0.44 is 23.94% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.45 $ 2.9266
 Low: $ 0.42 $ 0.355

Company Description (as filed with the SEC)

We are a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Drug-resistant infections account for two million illnesses in the United States and 700,000 deaths worldwide each year. We intend to address drug-resistant infections using product candidates from our lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. Lysins are enzymes derived from naturally occurring bacteriophage which are viruses that infect bacteria. When recombinantly produced and then applied to bacteria, lysins cleave a key component of the target bacteria's peptidoglycan cell wall, resulting in rapid bacterial cell death.  ... More ...  


Risk Grade

Where does CFRX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.4438
Open Date:
Feb. 15, 2019
Close Price:
$ 0.44
Close Date:
Feb. 15, 2019

Consensus Recommendation

Analyst Info